Merrimack Files S-1, But Life-Science IPO Market Far From Ironclad
This article was originally published in The Pink Sheet Daily
Executive Summary
The cancer drug maker aims to raise as much as $172.5 million and bring liquidity to investors who have poured in more than $250 million.
You may also be interested in...
Aveo Signs J&J As Partner In Early-Stage RON Antibody Deal
Given the early-stage nature of the collaboration, Aveo will receive $15 million upfront for preclinical antibodies targeting the RON receptor.
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
In a worldwide deal excluding Asia, the two companies will split both revenues and development costs 50/50 in North America and Europe.
Sanofi Broadens Portfolio By Licensing A Monoclonal Antibody From Merrimack
Privately held Merrimack gets $60 million upfront for MM-121, a monoclonal antibody in Phase I/II.